Abstracts Archive - Page 856 of 2607 - ACR Meeting Abstracts

Abstract Number: 0294 • ACR Convergence 2020
Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
Chris Wincup¹, Thomas McDonnell¹, George Robinson², Filipa Farinha¹, Anna Radziszewska¹ and Anisur Rahman¹, ¹University College London, London, United Kingdom, ²University College London, Hertford, United Kingdom
Background/Purpose: Iron is vital for many physiological processes and is found within respiratory complexes of the mitochondrial electron transport chain, the key site of oxidative phosphorylation…
Abstract Number: 0295 • ACR Convergence 2020
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Eunyoung Lee¹, Young-Ho Kim², Hye Won Sim², Eun-Kyung Kang², Yoon-Ho Won², Esther Park², Yeong-Wook Song³ and Kyeong-Man Hong², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²National Cancer Center, Ilsan, Kyonggi-do, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, Korea, Republic of Korea
Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has…
Abstract Number: 0296 • ACR Convergence 2020
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Carolina Munoz-grajales¹, Stephenie Prokopec², Dennisse Bonilla³, Earl D. Silverman⁴, Sindhu Johnson³, Arthur Bookman⁵, Zahi Touma⁶, Zareen Ahmad⁷, Linda Hiraki⁸, Paul Boutros⁹, Andrzej Chruscinski¹⁰ and Joan Wither³, ¹University of Toronto, Toronto, Canada, ²Ontario Institute for Cancer Research, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network; 8Department of Medicine, University of Toronto; Division of Rheumatology, Toronto, Canada, ⁶University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Department of Medicine, University of Toronto, Toronto, Canada, ⁹Department of Immunology, University of Toronto; Department of Medical Biophysics, University of Toronto; Department of Pharmacology and Toxicology, University of Toronto; Department of Human Genetics, University of California; Department of Urology, University of California; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California; Institute for Precision Health, University of California; Jonsson Comprehensive Cancer Centre, University of California, Toronto, Canada, ¹⁰Multi-Organ Transplant Program, University Health Network, Toronto, Canada
Background/Purpose: Within the Anti-Nuclear Antibody (ANA) associated Systemic Autoimmune Rheumatic Diseases (SARD), such as Systemic Lupus Erythematous (SLE), Sjögren’s Syndrome (SS), and Systemic Sclerosis (SSc),…
Abstract Number: 0297 • ACR Convergence 2020
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
Melissa Northcott¹, Linden Gearing², Hieu Nim³, Champa Nataraja³, Sarah Jones¹ and Eric Morand⁴, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ²Hudson Institute of Medical Research, Clayton, Victoria, Australia, ³Monash University, Clayton, Victoria, Australia, ⁴Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC), utilised in SLE for their broad immunosuppressive actions, predominantly mediate these effects by interaction with the cytoplasmic GC receptor (GR) to modulate…
Abstract Number: 0298 • ACR Convergence 2020
Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
Olivia Solomon¹, Cristina Lanata², Cameron Adams¹, Joanne Nititham³, Kim Taylor³, Sharon Chung³, Bernardo Pons-Estel⁴, Teresa Tusié-Luna⁵, Betty Tsao⁶, Eric Morand⁷, Marta Alarcón-Riquelme⁸, Lisa Barcellos¹ and Lindsey Criswell⁹, ¹University of California, Berkeley, Berkeley, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran and Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de Mexico, Mexico City, Mexico, ⁶Medical University of South Carolina, Charleston, ⁷Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical manifestations which are known to vary in severity by race. Health disparities in…
Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Ani Oganesyan¹, Jennifer Kelly², Stuart Glenn², Adam Adler², Adrienne Williams³, Mary Comeau⁴, Julia Ziegler⁵, Miranda Marion⁵, Marta Alarcón-Riquelme⁶, Graciela Alarcón⁷, Juan-Manuel Anaya⁸, Sang-Cheol Bae⁹, Dam Kim⁹, Lee Hye-Soon⁹, Lindsey Criswell¹⁰, Barry Freedman¹¹, Gary Gilkeson¹², Joel Guthridge¹³, Chaim Jacob¹⁴, Judith James¹⁵, Diane Kamen¹⁶, Joan Merrill¹⁷, Kathy Moser Silvis¹⁸, Timothy Niewold¹⁹, Michelle Petri²⁰, Rosalind Ramsey-Goldman²¹, John Reveille²², Hal Scofield²³, Anne Stevens²⁴, Luis Vilá²⁵, Timothy Vyse²⁶, Kenneth Kaufman²⁷, John Harley²⁸, Carl Langefeld⁵, Patrick Gaffney², Elizabeth Brown²⁹, Jeffrey Edberg⁷, Robert Kimberly⁷, Betty Tsao¹², Daniela Ulgiati³⁰, Kenneth Jones³¹ and Susan Boackle³², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Biostatistical Sciences and Center for Public Health Genomics Wake Forest School of Medicine, Winston-Salem,, NC, ⁴Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine; MC Analytics, Winston-Salem, NC, ⁵Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ⁹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ¹¹Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem,, NC, ¹²Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oaklahoma, OK, ¹⁴Department of Medicine, University of Southern California, Los Angeles, CA, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²²Department of Internal Medicine, University of Texas, Houston, TX, ²³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Charleston, SD, ²⁴Janssen Pharmaceuticals, Spring House, PA, ²⁵Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²⁶Division of Genetics and Molecular Medicine and Immunology, King’s College, London, United Kingdom, ²⁷Cincinnati Children’s Hospital Medical Center;US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁸Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ²⁹Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, ³⁰School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Australia, ³¹Harold Hamm Diabetes Center, University of Oklahoma Health Science Center, Oklahoma City, OK, ³²Division of Rheumatology, University of Colorado School of Medicine; Denver Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0301 • ACR Convergence 2020
Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Matthew Slief¹, Jeremy Levin², Susan Macwana¹, Wade DeJager¹, Rebecka Bourn³, Swapan Nath³, Melissa Munroe⁴, Teresa Aberle¹, Patrick Gaffney⁵, Joan Merrill³, Judith James⁶ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OU Medical Center, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Patients with incomplete lupus erythematosus (ILE) have features of lupus, but have insufficient criteria for SLE classification. Some ILE patients transition to classified SLE,…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 0303 • ACR Convergence 2020
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
Kieran Manion¹, Carolina Munoz-Grajales², Michael Kim³, Kirubel Goliad⁴, Dennisse Bonilla⁵, Dafna Gladman¹, Murray Urowitz⁶, Zahi Touma⁷ and Joan Wither⁵, ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto-UHN, Toronto, ON, Canada, ³Krembil Research Insitute, Toronto, ON, Canada, ⁴University of Toronto-UHN, Toronto, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE is a chronic autoimmune disease in which periods of quiescence are interspersed with acute flares of disease activity that produce much of the…
Abstract Number: 0304 • ACR Convergence 2020
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Wendy Dankers¹, Melissa Northcott², Taylah Bennett³, Brendan Russ³, Jacqueline Flynn¹, Sarah Jones² and Eric Morand¹, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ³Department of Microbiology, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
Abstract Number: 0305 • ACR Convergence 2020
A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis
Rebecca Haberman¹, Lourdes Perez-Chada², Vinod Chandran³, Cheryl Rosen⁴, Christopher Ritchlin⁵, Lihi Eder⁶, Philip Mease⁷, Soumya Reddy⁸, Alexis Ogdie⁹, Joseph Merola¹⁰ and Jose Scher¹, ¹NYU School of Medicine, New York City, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁶Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁸NYU School of Medicine, New York, NY, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The concept of prevention of psoriatic arthritis (PsA) has gained increased interest given the physical limitation and poor quality-of-life experienced by PsA patients coupled…
Abstract Number: 0306 • ACR Convergence 2020
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Taylor Blachley², Kelechi Emeanuru², Sven Richter³, Benoit Guerette³ and Philip Mease⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Amgen Inc., Thousand Oaks, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…
Abstract Number: 0307 • ACR Convergence 2020
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Alexis Ogdie¹, Martin Rozycki², Theresa Arndt², Cheng Shi³, Nina Kim⁴ and Peter Hur³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴The University of Texas at Austin; Baylor Scott and White Health, Austin, TX
Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
Abstract Number: 0308 • ACR Convergence 2020
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
Paras Karmacharya¹, Kerry Wright², Sara J. Achenbach³, Delamo Bekele², Cynthia Crowson⁴, Alexis Ogdie⁵, Ali Duarte-Garcia², Floranne C. Ernste³, Megha M. Tollefson¹ and John Davis², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently or after the development of psoriasis. In order to better understand the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].